Ziopharm to present data on Controlled IL-12 studies at ASCO meeting
Ziopharm Oncology announced last night that clinical data showing the company's Controlled IL-12 platform "elicits a sustained increase in killer T cells with a good safety profile in patients with breast cancer and patients with brain cancer" has been accepted for presentation at the 2018 American Society of Clinical Oncology, or ASCO, Annual Meeting. "Intratumoral injection of Ad-RTS-hIL-12 plus oral doses of veledimex clearly demonstrate ability to turn cold tumors hot and bring to tumors cancer-fighting T cells that were not there before. These data support further development of our Controlled IL-12 platform in combination with immune checkpoint inhibitors, and we have one combination trial initiated in brain cancer and plans to advance a second tumor type later this year," said Francois Lebel. Ziopharm's Chief Medical Officer and Executive VP for Research & Development.